K. W. Lam

Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study

Yang Liu, S. Koletar, J. Lake, 2022, The Lancet Infectious Diseases.

Short‐duration treatment with the novel non‐nucleoside inhibitor CDI‐31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open‐label study

A. Ntem-Mensah, B. Poonia, Sam S Lee, 2020, Journal of medical virology.

Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial

D. Montefiori, R. Gottardo, G. Ferrari, 2021, Vaccine.